{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:44:07Z","timestamp":1793727847885,"version":"4.6.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"DOI":"10.1007\/s11883-025-01382-z","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T07:51:22Z","timestamp":1768290682000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Colchicine in Coronary Artery Disease: Comparative Review of CLEAR SYNERGY, LoDoCo2 and COLCOT"],"prefix":"10.1007","volume":"28","author":[{"given":"Jalina","family":"Jannink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aim\u00e9e MH","family":"van Zelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumaya","family":"Chemlal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice MAC","family":"Martens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel HF","family":"Poorthuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank LJ","family":"Visseren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arend","family":"Mosterd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aernoud TL","family":"Fiolet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"1382_CR1","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1056\/NEJMra2000317","volume":"383","author":"R Vergallo","year":"2020","unstructured":"Vergallo R, Crea F. Atherosclerotic plaque healing. N Engl J Med. 2020;383:846\u201357. https:\/\/doi.org\/10.1056\/NEJMra2000317.","journal-title":"N Engl J Med"},{"key":"1382_CR2","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41586-021-03392-8","volume":"592","author":"P Libby","year":"2021","unstructured":"Libby P. The changing landscape of atherosclerosis. Nature. 2021;592:524\u201333. https:\/\/doi.org\/10.1038\/s41586-021-03392-8.","journal-title":"Nature"},{"key":"1382_CR3","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3389\/fcvm.2020.00088","volume":"7","author":"DS Dhindsa","year":"2020","unstructured":"Dhindsa DS, Sandesara PB, Shapiro MD, et al. The evolving understanding and approach to residual cardiovascular risk management. Front Cardiovasc Med. 2020;7:88. https:\/\/doi.org\/10.3389\/fcvm.2020.00088.","journal-title":"Front Cardiovasc Med"},{"key":"1382_CR4","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S0140-6736(23)00215-5","volume":"401","author":"PM Ridker","year":"2023","unstructured":"Ridker PM, Bhatt DL, Pradhan AD, et al. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials. Lancet. 2023;401:1293\u2013301. https:\/\/doi.org\/10.1016\/S0140-6736(23)00215-5.","journal-title":"Lancet"},{"key":"1382_CR5","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with Canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1707914.","journal-title":"N Engl J Med"},{"key":"1382_CR6","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1161\/CIRCULATIONAHA.120.050560","volume":"142","author":"TSJ Opstal","year":"2020","unstructured":"Opstal TSJ, Hoogeveen RM, Fiolet ATL, et al. Colchicine attenuates inflammation beyond the inflammasome in chronic coronary artery disease: a LoDoCo2 proteomic substudy. Circulation. 2020;142:1996\u20138. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.050560.","journal-title":"Circulation"},{"key":"1382_CR7","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.semarthrit.2015.06.013","volume":"45","author":"YY Leung","year":"2015","unstructured":"Leung YY, Yao Hui LL, Kraus VB. Colchicine\u2013update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015;45:341\u201350. https:\/\/doi.org\/10.1016\/j.semarthrit.2015.06.013.","journal-title":"Semin Arthritis Rheum"},{"key":"1382_CR8","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1042\/CS20160090","volume":"130","author":"S Robertson","year":"2016","unstructured":"Robertson S, Mart\u00ednez GJ, Payet CA, et al. Colchicine therapy in acute coronary syndrome patients acts on caspase-1 to suppress NLRP3 inflammasome monocyte activation. Clin Sci (Lond). 2016;130:1237\u201346. https:\/\/doi.org\/10.1042\/CS20160090.","journal-title":"Clin Sci (Lond)"},{"key":"1382_CR9","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.atherosclerosis.2017.12.027","volume":"269","author":"GJ Mart\u00ednez","year":"2018","unstructured":"Mart\u00ednez GJ, Celermajer DS, Patel S. The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. Atherosclerosis. 2018;269:262\u201371. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.12.027.","journal-title":"Atherosclerosis"},{"key":"1382_CR10","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002128","volume":"4","author":"GJ Mart\u00ednez","year":"2015","unstructured":"Mart\u00ednez GJ, Robertson S, Barraclough J, et al. Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome. J Am Heart Assoc. 2015;4:e002128. https:\/\/doi.org\/10.1161\/JAHA.115.002128.","journal-title":"J Am Heart Assoc"},{"key":"1382_CR11","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1172\/JCI118147","volume":"96","author":"BN Cronstein","year":"1995","unstructured":"Cronstein BN, Molad Y, Reibman J, et al. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest. 1995;96:994\u20131002. https:\/\/doi.org\/10.1172\/JCI118147.","journal-title":"J Clin Invest"},{"key":"1382_CR12","doi-asserted-by":"publisher","first-page":"898690","DOI":"10.3389\/fimmu.2022.898690","volume":"13","author":"U Meyer-Lindemann","year":"2022","unstructured":"Meyer-Lindemann U, Mauersberger C, Schmidt A-C, et al. Colchicine impacts leukocyte trafficking in atherosclerosis and reduces vascular inflammation. Front Immunol. 2022;13:898690. https:\/\/doi.org\/10.3389\/fimmu.2022.898690.","journal-title":"Front Immunol"},{"key":"1382_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12950-023-00366-7","volume":"20","author":"H Zhou","year":"2023","unstructured":"Zhou H, Khan D, Hussain SM, et al. Colchicine prevents oxidative stress-induced endothelial cell senescence via blocking NF-\u03baB and MAPKs: implications in vascular diseases. J Inflamm. 2023;20:41. https:\/\/doi.org\/10.1186\/s12950-023-00366-7.","journal-title":"J Inflamm"},{"key":"1382_CR14","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/nature08938","volume":"464","author":"P Duewell","year":"2010","unstructured":"Duewell P, Kono H, Rayner KJ, et al. Nlrp3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464:1357\u201361. https:\/\/doi.org\/10.1038\/nature08938.","journal-title":"Nature"},{"key":"1382_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2025.119239","volume":"406","author":"A von Ehr","year":"2025","unstructured":"von Ehr A, Steenbuck ID, H\u00e4fele C, et al. Experimental evidence on colchicine\u2019s mode of action in human carotid artery plaques. Atherosclerosis. 2025;406:119239. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.119239.","journal-title":"Atherosclerosis"},{"key":"1382_CR16","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.018993","volume":"10","author":"K Vaidya","year":"2021","unstructured":"Vaidya K, Tucker B, Kurup R, et al. Colchicine inhibits neutrophil extracellular trap formation in patients with acute coronary syndrome after percutaneous coronary intervention. J Am Heart Assoc. 2021;10:e018993. https:\/\/doi.org\/10.1161\/JAHA.120.018993.","journal-title":"J Am Heart Assoc"},{"key":"1382_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10557-022-07326-y","volume":"38","author":"Y-W Li","year":"2024","unstructured":"Li Y-W, Chen S-X, Yang Y, et al. Colchicine inhibits NETs and alleviates cardiac remodeling after acute myocardial infarction. Cardiovasc Drugs Ther. 2024;38:31\u201341. https:\/\/doi.org\/10.1007\/s10557-022-07326-y.","journal-title":"Cardiovasc Drugs Ther"},{"key":"1382_CR18","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","volume":"61","author":"SM Nidorf","year":"2013","unstructured":"Nidorf SM, Eikelboom JW, Budgeon CA, et al. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61:404\u201310. https:\/\/doi.org\/10.1016\/j.jacc.2012.10.027.","journal-title":"J Am Coll Cardiol"},{"key":"1382_CR19","doi-asserted-by":"publisher","first-page":"e0237665","DOI":"10.1371\/journal.pone.0237665","volume":"15","author":"ATL Fiolet","year":"2020","unstructured":"Fiolet ATL, Silvis MJM, Opstal TSJ, et al. Short-term effect of low-dose Colchicine on inflammatory biomarkers, lipids, blood count and renal function in chronic coronary artery disease and elevated high-sensitivity C-reactive protein. PLoS One. 2020;15:e0237665. https:\/\/doi.org\/10.1371\/journal.pone.0237665.","journal-title":"PLoS One"},{"key":"1382_CR20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ijcard.2022.06.028","volume":"363","author":"M Sun","year":"2022","unstructured":"Sun M, Dub\u00e9 M-P, Hennessy T, et al. Low-dose colchicine and high-sensitivity C-reactive protein after myocardial infarction: a combined analysis using individual patient data from the COLCOT and LoDoCo-MI studies. Int J Cardiol. 2022;363:20\u20132. https:\/\/doi.org\/10.1016\/j.ijcard.2022.06.028.","journal-title":"Int J Cardiol"},{"key":"1382_CR21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.tox.2011.03.015","volume":"285","author":"JP Rigalli","year":"2011","unstructured":"Rigalli JP, Ruiz ML, Perdomo VG, et al. Pregnane X receptor mediates the induction of P-glycoprotein by spironolactone in HepG2 cells. Toxicology. 2011;285:18\u201324. https:\/\/doi.org\/10.1016\/j.tox.2011.03.015.","journal-title":"Toxicology"},{"key":"1382_CR22","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s40264-022-01265-1","volume":"46","author":"PD Hansten","year":"2023","unstructured":"Hansten PD, Tan MS, Horn JR, et al. Colchicine drug interaction errors and misunderstandings: recommendations for improved evidence-based management. Drug Saf. 2023;46:223\u201342. https:\/\/doi.org\/10.1007\/s40264-022-01265-1.","journal-title":"Drug Saf"},{"key":"1382_CR23","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1056\/NEJMe2416329","volume":"392","author":"J Loscalzo","year":"2025","unstructured":"Loscalzo J. Timing the taming of vascular inflammation. N Engl J Med. 2025;392:712\u20134. https:\/\/doi.org\/10.1056\/NEJMe2416329.","journal-title":"N Engl J Med"},{"key":"1382_CR24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.119.008717","volume":"13","author":"B Shah","year":"2020","unstructured":"Shah B, Pillinger M, Zhong H, et al. Effects of Acute Colchicine Administration Prior to Percutaneous Coronary Intervention: COLCHICINE-PCI Randomized Trial. Circ Cardiovasc Interv. 2020;13:e008717. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.119.008717.","journal-title":"Circ Cardiovasc Interv"},{"key":"1382_CR25","doi-asserted-by":"publisher","first-page":"4092","DOI":"10.1093\/eurheartj\/ehaa659","volume":"41","author":"N Bouabdallaoui","year":"2020","unstructured":"Bouabdallaoui N, Tardif J-C, Waters DD, et al. Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). Eur Heart J. 2020;41:4092. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa659.","journal-title":"Eur Heart J"},{"key":"1382_CR26","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1161\/CIRCULATIONAHA.120.050771","volume":"142","author":"DC Tong","year":"2020","unstructured":"Tong DC, Quinn S, Nasis A, et al. Colchicine in patients with acute coronary syndrome: the Australian COPS randomized clinical trial. Circulation. 2020;142:1890\u2013900. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.050771.","journal-title":"Circulation"},{"key":"1382_CR27","doi-asserted-by":"publisher","unstructured":"Bodilsen J, Nielsen PB, S\u00f8gaard M, et al. Hospital admission and mortality rates for non-covid diseases in Denmark during covid-19 pandemic: nationwide population based cohort study. BMJ. 2021;n1135. https:\/\/doi.org\/10.1136\/bmj.n1135.","DOI":"10.1136\/bmj.n1135"},{"key":"1382_CR28","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1093\/ehjacc\/zuae135","volume":"13","author":"J-C Tardif","year":"2024","unstructured":"Tardif J-C, Kouz S. Efficacy and safety of Colchicine and spironolactone after myocardial infarction: the CLEAR-SYNERGY trial in perspective. Eur Heart J Acute Cardiovasc Care. 2024;13:843\u20134. https:\/\/doi.org\/10.1093\/ehjacc\/zuae135.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"1382_CR29","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40471-014-0027-z","volume":"1","author":"MJ Funk","year":"2014","unstructured":"Funk MJ, Landi SN. Misclassification in administrative claims data: quantifying the impact on treatment effect estimates. Curr Epidemiol Rep. 2014;1:175\u201385. https:\/\/doi.org\/10.1007\/s40471-014-0027-z.","journal-title":"Curr Epidemiol Rep"},{"key":"1382_CR30","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1056\/NEJMoa1907775","volume":"381","author":"SR Mehta","year":"2019","unstructured":"Mehta SR, Wood DA, Storey RF, et al. Complete revascularization with multivessel PCI for myocardial infarction. N Engl J Med. 2019;381:1411\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1907775.","journal-title":"N Engl J Med"},{"key":"1382_CR31","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1056\/NEJMoa1701067","volume":"376","author":"PC Smits","year":"2017","unstructured":"Smits PC, Abdel-Wahab M, Neumann F-J, et al. Fractional flow reserve\u2013guided multivessel angioplasty in myocardial infarction. N Engl J Med. 2017;376:1234\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1701067.","journal-title":"N Engl J Med"},{"key":"1382_CR32","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","volume":"381","author":"J-C Tardif","year":"2019","unstructured":"Tardif J-C, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381:2497\u2013505. https:\/\/doi.org\/10.1056\/NEJMoa1912388.","journal-title":"N Engl J Med"},{"key":"1382_CR33","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","volume":"383","author":"SM Nidorf","year":"2020","unstructured":"Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383:1838\u201347. https:\/\/doi.org\/10.1056\/NEJMoa2021372.","journal-title":"N Engl J Med"},{"key":"1382_CR34","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","volume":"45","author":"C Vrints","year":"2024","unstructured":"Vrints C, Andreotti F, Koskinas KC, et al. 2024 ESC guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45:3415\u2013537. https:\/\/doi.org\/10.1093\/eurheartj\/ehae177.","journal-title":"Eur Heart J"},{"key":"1382_CR35","doi-asserted-by":"publisher","unstructured":"Virani SS, Newby LK, Arnold SV, et al. 2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: A report of the American heart Association\/American college of cardiology joint committee on clinical practice guidelines. Circulation. 2023;148. https:\/\/doi.org\/10.1161\/CIR.0000000000001168.","DOI":"10.1161\/CIR.0000000000001168"},{"key":"1382_CR36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405922","author":"SS Jolly","year":"2024","unstructured":"Jolly SS, d\u2019Entremont M-A, Lee SF, et al. Colchicine in acute myocardial infarction. N Eng J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2405922.","journal-title":"N Eng J Med"},{"key":"1382_CR37","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1056\/NEJMoa2405923","volume":"392","author":"SS Jolly","year":"2025","unstructured":"Jolly SS, d\u2019Entremont M-A, Pitt B, et al. Routine spironolactone in acute myocardial infarction. N Engl J Med. 2025;392:643\u201352. https:\/\/doi.org\/10.1056\/NEJMoa2405923.","journal-title":"N Engl J Med"},{"key":"1382_CR38","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/0014-4827(92)90284-f","volume":"201","author":"L Santell","year":"1992","unstructured":"Santell L, Marotti K, Bartfeld NS, et al. Disruption of microtubules inhibits the stimulation of tissue plasminogen activator expression and promotes plasminogen activator inhibitor type 1 expression in human endothelial cells. Exp Cell Res. 1992;201:358. https:\/\/doi.org\/10.1016\/0014-4827(92)90284-f.","journal-title":"Exp Cell Res"},{"key":"1382_CR39","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1006\/excr.1998.4133","volume":"243","author":"K Kielbassa","year":"1998","unstructured":"Kielbassa K, Schmitz C, Gerke V. Disruption of endothelial microfilaments selectively reduces the transendothelial migration of monocytes. Exp Cell Res. 1998;243:129\u201341. https:\/\/doi.org\/10.1006\/excr.1998.4133.","journal-title":"Exp Cell Res"},{"key":"1382_CR40","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1161\/CIRCULATIONAHA.124.069808","volume":"150","author":"M Yu","year":"2024","unstructured":"Yu M, Yang Y, Dong S-L, et al. Effect of Colchicine on coronary plaque stability in acute coronary syndrome as assessed by optical coherence tomography: the COLOCT randomized clinical trial. Circulation. 2024;150:981\u201393. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.069808.","journal-title":"Circulation"},{"key":"1382_CR41","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ahj.2024.09.006","volume":"278","author":"CA Budgeon","year":"2024","unstructured":"Budgeon CA, Nidorf S, Mosterd A, et al. Exploration of the regional effects of colchicine in the LoDoCo2 trial. Am Heart J. 2024;278:186\u201394. https:\/\/doi.org\/10.1016\/j.ahj.2024.09.006.","journal-title":"Am Heart J"},{"key":"1382_CR42","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","volume":"131","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Assmann SF, et al. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation. 2015;131:34\u201342. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.013255.","journal-title":"Circulation"},{"key":"1382_CR43","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1056\/NEJMra1510065","volume":"375","author":"S Yusuf","year":"2016","unstructured":"Yusuf S, Wittes J. Interpreting geographic variations in results of randomized, controlled trials. N Engl J Med. 2016;375:2263\u201371. https:\/\/doi.org\/10.1056\/NEJMra1510065.","journal-title":"N Engl J Med"},{"key":"1382_CR44","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1056\/NEJMc2015630","volume":"383","author":"MD Solomon","year":"2020","unstructured":"Solomon MD, McNulty EJ, Rana JS, et al. The COVID-19 pandemic and the incidence of acute myocardial infarction. N Engl J Med. 2020;383:691\u20133. https:\/\/doi.org\/10.1056\/NEJMc2015630.","journal-title":"N Engl J Med"},{"key":"1382_CR45","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jacc.2020.05.038","volume":"76","author":"AS Bhatt","year":"2020","unstructured":"Bhatt AS, Moscone A, McElrath EE, et al. Fewer hospitalizations for acute cardiovascular conditions during the COVID-19 pandemic. J Am Coll Cardiol. 2020;76:280\u20138. https:\/\/doi.org\/10.1016\/j.jacc.2020.05.038.","journal-title":"J Am Coll Cardiol"},{"key":"1382_CR46","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1093\/ehjqcco\/qcad048","volume":"10","author":"F Sofi","year":"2024","unstructured":"Sofi F, Dinu M, Reboldi G, et al. Worldwide impact of COVID-19 on hospital admissions for non-ST-elevation acute coronary syndromes (NSTACS): a systematic review with meta-analysis of 553 038 cases. Eur Heart J Qual Care Clin Outcomes. 2024;10:265\u201383. https:\/\/doi.org\/10.1093\/ehjqcco\/qcad048.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"1382_CR47","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1093\/eurheartj\/ehab115","volume":"42","author":"ATL Fiolet","year":"2021","unstructured":"Fiolet ATL, Opstal TSJ, Mosterd A, et al. Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. Eur Heart J. 2021;42:2765\u201375. https:\/\/doi.org\/10.1093\/eurheartj\/ehab115.","journal-title":"Eur Heart J"},{"key":"1382_CR48","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1093\/eurheartj\/ehy310","volume":"39","author":"PM Ridker","year":"2018","unstructured":"Ridker PM, Libby P, MacFadyen JG, et al. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Eur Heart J. 2018;39:3499\u2013507. https:\/\/doi.org\/10.1093\/eurheartj\/ehy310.","journal-title":"Eur Heart J"},{"key":"1382_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.08.025","author":"N Mohammadnia","year":"2025","unstructured":"Mohammadnia N, Xue L, Vestjens LTW, et al. Colchicine and longitudinal dynamics of clonal hematopoiesis: an exploratory substudy of the LoDoCo2 Trial. JACC. 2025. https:\/\/doi.org\/10.1016\/j.jacc.2025.08.025.","journal-title":"JACC"},{"key":"1382_CR50","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf210","author":"M-A d\u2019Entremont","year":"2025","unstructured":"d\u2019Entremont M-A, Poorthuis MHF, Fiolet ATL, et al. Colchicine for secondary prevention of vascular events: a meta-analysis of trials. Eur Heart J. 2025. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf210.","journal-title":"Eur Heart J"},{"key":"1382_CR51","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1093\/eurheartj\/ehaf174","volume":"46","author":"M Samuel","year":"2025","unstructured":"Samuel M, Berry C, Dub\u00e9 M-P, et al. Long-term trials of colchicine for secondary prevention of vascular events: a meta-analysis. Eur Heart J. 2025;46:2552\u201363. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf174.","journal-title":"Eur Heart J"},{"key":"1382_CR52","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"A Randomized Trial of Intensive versus Standard Blood-Pressure Control","year":"2015","unstructured":"A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373:2103\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1511939.","journal-title":"N Engl J Med"},{"key":"1382_CR53","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097\u2013107. https:\/\/doi.org\/10.1056\/NEJMoa1801174.","journal-title":"N Engl J Med"},{"key":"1382_CR54","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1615664.","journal-title":"N Engl J Med"},{"key":"1382_CR55","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1410489.","journal-title":"N Engl J Med"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-025-01382-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-025-01382-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-025-01382-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T22:18:16Z","timestamp":1768342696000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-025-01382-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1382"],"URL":"https:\/\/doi.org\/10.1007\/s11883-025-01382-z","relation":{},"ISSN":["1534-6242"],"issn-type":[{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"assertion":[{"value":"16 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No animal or human subjects were used in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"11"}}